TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04628767
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04628767
Drug: Vinblastine Sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given Iv
Study: NCT05189457
Drug: Luteinizing Hormone Releasing Hormone
Normalized name: Luteinizing hormone releasing hormone
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
Study: NCT05189457
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel.
Study: NCT05189457
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
Study: NCT04555343
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1gm instilled instravesically
Study: NCT05908786
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
Study: NCT05908786
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
Study: NCT05908786
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
Study: NCT05908786
Drug: Tobemstomig
Normalized name: Tobemstomig
DrugBank: Tobemstomig (DB18987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
Study: NCT05135559
Drug: Concizumab
Normalized name: concizumab
DrugBank: Concizumab (DB12820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.
Study: NCT03617445
Drug: FMT oral capsule
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT oral capsules, single dose of 5 capsules
Study: NCT03617445
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
Study: NCT06266988
Drug: Sacubitril and Valsartan Tablets 97mg/103mg
Normalized name: valsartan and sacubitril
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan
Study: NCT06266988
Drug: Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)
Normalized name: Entresto
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
Study: NCT00117455
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00117455
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06452394
Drug: Doxycyclin
Normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit
Study: NCT04134052
Drug: ketamine sedation versus midazolam sedation
Normalized name: Tavist Non-Sedating
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
Study: NCT01928069
Drug: Torrent's Montelukast Sodium Tablets 10 mg
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04920344
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
Study: NCT05485584
Drug: rSIFN-co Nasal Spray
Normalized name: rSIFN-co
DrugBank: Recombinant Super-Compound Interferon (DB15752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 million IU (16 μg)/day; Once daily
Study: NCT05485584
Drug: rSIFN-co Nasal Spray
Normalized name: rSIFN-co
DrugBank: Recombinant Super-Compound Interferon (DB15752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 million IU (32 μg)/day; Twice daily
Study: NCT05961709
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV (vein)
Study: NCT05864144
Drug: SNS-101 (anti-VISTA)
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNS-101 IV every 21 days.
Study: NCT05864144
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab IV every 21 days.
Study: NCT05245006
Drug: 89Zr-DFO-YS5
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mCi will be administered intravenously
Study: NCT05974501
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
Study: NCT05974501
Drug: Lyrica
Normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
Study: NCT05974501
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
Study: NCT05974501
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
Study: NCT05974501
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
Study: NCT05040568
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05040568
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06566170
Drug: Donanemab
Normalized name: Donanemab
DrugBank: Donanemab (DB16647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06055309
Drug: Cannabis (up to three doses)
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a dose of cannabis will be baked into brownies
Study: NCT04863885
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Ipilimumab 3 mg/kg
Study: NCT04863885
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Nivoumab 1mg/kg
Study: NCT04863885
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
Study: NCT05668429
Drug: Ibrexafungerp
Normalized name: Ibrexafungerp
DrugBank: Ibrexafungerp (DB12471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carbon-14 (\[14\^C\])-Ibrexafungerp
Study: NCT05870761
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05944783
Drug: Dasatinib 100 MG
Normalized name: dasatinib 100 MG
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose of 100 mg Dasatinib tablets
Study: NCT05285943
Drug: Olive oil cream
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil prepared in a base cream to be applied to irradiated areas.
Study: NCT05285943
Drug: Betamethasone Valerate Cream
Normalized name: Betamethasone Valerate Cream
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
Study: NCT05299125
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
Study: NCT05299125
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
Study: NCT05299125
Drug: Pemetrexed 500 mg
Normalized name: pemetrexed 500 MG
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
Study: NCT06177522
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg，i.v. , q3w
Study: NCT06177522
Drug: albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m2, i.v.,d1,d8, q3w
Study: NCT06177522
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0 g/m2, i.v.,d1, d8, q3w
Study: NCT06151574
Drug: zongertinib
Normalized name: Zongertinib
DrugBank: Zongertinib (DB18762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zongertinib
Study: NCT06151574
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab
Study: NCT06151574
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: platinum-pemetrexed chemotherapy
Study: NCT06151574
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: platinum-pemetrexed chemotherapy
Study: NCT06151574
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: platinum-pemetrexed chemotherapy
Study: NCT05143281
Drug: Dexamethasone 0.4 MG [Dextenza]
Normalized name: dexamethasone 0.4 MG [Dextenza]
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ophthalmic Intracanalicular Insert
Study: NCT06205602
Drug: 10-1074-LS
Normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg to be administered intravenously at Step 1 (Day 1)
Study: NCT05896527
Drug: DC-806
Normalized name: DCS
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DC-806 will be supplied as tablets to be administered orally.
Study: NCT05618587
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
Study: NCT05175508
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
Study: NCT05175508
Drug: all trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA 20mg tid by po on days 1-21 of every cycle 28 days
Study: NCT05353179
Drug: Meperizumab injection
Normalized name: mepolizumab Injection
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
Study: NCT06097169
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Study: NCT05023863
Drug: Alpha Lipoic Acid 600 MG Oral Tablets
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
Study: NCT05233618
Drug: Tagraxofusp
Normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
Study: NCT05557565
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
Study: NCT05772429
Drug: Epidiolex
Normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as an oral solution
Study: NCT05287984
Drug: Zanubrutinib, bendamustine, rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients older than 65 years or who cannot tolerate FCR regimens.
Study: NCT06668441
Drug: Minimally invasive surgery plus low-dose rhTNK-tPA group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.001mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
Study: NCT06668441
Drug: Minimally invasive surgery plus medium dose rhTNK-tPA group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.003mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
Study: NCT06668441
Drug: Minimally invasive surgery plus high dose rhTNK-tPA group
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.009mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
Study: NCT06536517
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
Study: NCT05993767
Drug: dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
Study: NCT05993767
Drug: Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF)
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single arm
Study: NCT06544434
Drug: Betahistine Mesylate tablet
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
Study: NCT04974151
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The amlodipine used in this study is a listed product.
Study: NCT04974151
Drug: 5-methyltetrahydrofolate (5-MTHF)
Normalized name: 5-METHYLTETRAHYDROFOLIC ACID
DrugBank: 5-methyltetrahydrofolic acid (DB04789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 5-MTHF used in this study is a listed product.
Study: NCT06319378
Drug: psilocybin 25 mg sod
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: psilocybin 25 mg sod
Study: NCT06319378
Drug: psilocybin 1 mg sod
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active placebo
Study: NCT06558045
Drug: Rivaroxaban 20 mg film-coated tablet
Normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
Study: NCT06558045
Drug: Xarelto 20 mg film-coated tablet
Normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
Study: NCT04974151
Drug: Amlodipine placebo
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine placebos are dummy pills of amlodipine with identical appearance.
Study: NCT04974151
Drug: 5-MTHF Placebos
Normalized name: (6S)-5-MTHF
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.
Study: NCT06054893
Drug: Omaveloxolone
Normalized name: Omaveloxolone
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06390319
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO) or intravenously (IV).
Study: NCT06390319
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT06390319
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT06390319
Drug: Calaspargase pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT06390319
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06390319
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO (ETP, near-ETP, and MPAL only).
Study: NCT06390319
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV (T-LLy only).
Study: NCT06390319
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given Intrathecal (IT), Age adjusted.
Study: NCT06390319
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT.
Study: NCT06390319
Drug: Nelarabine
Normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06390319
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO (participants intolerant to mercaptopurine).
Study: NCT04731376
Drug: Testosterone Cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT06452277
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06452277
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06452277
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion